Semaglutide linked to improved eating disorder symptoms and body image in obesity study
A new 60-week study led by researchers at the Perelman School of Medicine at the University of Pennsylvania suggests that semaglutide may improve disordered eating symptoms and body image concerns in adults seeking obesity treatment.
🔬ResearchPhoto: Medical Xpress
Key points
- Study tracked 120 adults over 60 weeks comparing semaglutide 2.4 mg to a placebo.
- Semaglutide group lost roughly 15% of body weight compared to 3% for placebo.
- Trial noted reductions in loss-of-control eating and higher binge eating remission rates.
Adults taking the medication semaglutide for weight management experienced greater enhancements in several measures of disordered eating and body image compared to participants given a placebo, according to research published in the International Journal of Eating Disorders. The findings were presented at ObesityWeek 2026 in Washington, D.C., by investigators from the Perelman School of Medicine at the University of Pennsylvania.
The randomized, placebo-controlled trial followed 120 adults seeking treatment for obesity over 60 weeks, combining the treatments with structured lifestyle interventions involving dietary counseling and physical activity guidance. Participants receiving 2.4 mg of semaglutide achieved an average weight loss of roughly 15% of their initial body weight, while the placebo group lost about 3%. Beyond weight reduction, the semaglutide group demonstrated significant decreases in loss-of-control eating, general eating disorder psychopathology, and shape or weight concerns.
Furthermore, individuals in the medication group who entered the study with binge eating episodes or related disorders showed higher rates of remission and abstinence from those behaviors. Researchers noted that while the overall outcomes were positive, a small subset of participants still developed disordered eating symptoms during the trial. This emphasizes the need for ongoing behavioral monitoring, particularly for patients with a documented history of eating disorders. The authors caution that larger studies are required to fully understand the connection between GLP-1 receptor agonists and eating disorder psychopathology.
What to know: While semaglutide showed promising results in reducing binge eating and improving body image alongside weight loss, experts emphasize regular clinical monitoring for eating behaviors during treatment. Always consult a qualified healthcare provider for personal medical decisions and tailored treatment plans.
Source Medical Xpress — medicalxpress.com/news/2026-11-semaglutide-disorder-symptoms-body-image… ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…